ChitomurЧитомур
A peptide mixture extracted from animal bladder wall, studied in institute reports on urinary symptoms.
What the studies found
Randomized study in people · 2013
Oral Chitomur versus capsule placebo in men with benign prostatic hyperplasia
- Peak urinary flow · post-course
- 12.7 vs 9.4 mL/sChitomur versus placebo. One month later, 10.36 vs 8.3 mL/s.Table 1 marks p < 0.001 versus placebo at the post-course visit only.
- Post-void residual urine · post-course
- 23.2 vs 72.1 mLOne month later, 48.7 vs 69.8 mL.Table 1 marks p < 0.001 versus placebo at both times.
- International Prostate Symptom Score · post-course
- 13.2 vs 15.6 pointsOne month later, 15.7 vs 17.9. The table gives a single 17.4-point baseline.Table 2 marks p < 0.001 versus placebo at the post-course visit only.
Post-course peak urinary flow was 12.7 vs 9.4 mL/s and prostate symptom scores were 13.2 vs 15.6 with Chitomur versus placebo. Prostate volume showed no significant change.
More reported outcomes
- Prostate volume and mean flow
- No significant prostate-volume changeThe table gives no significance marker for mean urinary flow.
- Adverse events
- None reported among Chitomur recipientsThe paper gives no systematic harms table.
Study notes · methods, sources and limitations
Participants or model 50 men aged 62–83 with benign prostatic hyperplasia. Chitomur 30, capsule placebo 20.
Design Chitomur 30 versus capsule placebo 20. Uroflowmetry, post-void residual volume, prostate ultrasound, and IPSS and quality-of-life questionnaires.
Important limitations
- Methods describe a blinded randomized study and the conclusion calls it open. The accessible report does not explain concealment, masking or placebo contents. Tables use a single baseline column and the reported endpoint timing varies. The sample and follow-up are too limited to characterize uncommon harms.
- The small study reported differences in urinary symptoms and function; prostate size did not measurably change. The conflict about masking limits confidence.
Advances in Gerontology / Uspekhi Gerontologii. 2013;26(3):476–480. PMID 24640697. · Journal article — commercial reproduction
Randomized study in people · 2013
Oral Chitomur versus usual treatment in women with overactive bladder
- Urgency episodes · around day 15
- 4.05 → 2.83 vs 4.62 → 3.11Chitomur versus usual care, each compared with its own baseline. Later values 3.26 and 2.67.
- Incontinence episodes · around day 15
- 1.34 → 0.83 vs 1.62 → 0.77Later values 0.91 and 0.61. Tables give within-group tests.
- ICIQ-LUTS symptom score · around day 15
- 8.75 → 6.63 vs 8.25 → 5.72Later values 7.23 and 4.60.
Urgency episodes fell from 4.05 to 2.83 with Chitomur and from 4.62 to 3.11 with usual care around day 15. Later counts were 3.26 and 2.67, respectively.
More reported outcomes
- Reported adverse events
- 0/30 vs 7/20Usual-care events included dry mouth and constipation. The drugs and ascertainment protocol are unspecified.
Study notes · methods, sources and limitations
Participants or model 50 women aged 48–80 with overactive bladder. Chitomur 30, usual care 20.
Design Chitomur 30 versus usual care 20. Bladder diaries and validated symptom questionnaires at baseline and around 15 and 45 days from treatment start.
Important limitations
- The reproduction describes blinded random allocation without explaining concealment or how masking worked. Comparator drug schedules are unspecified. Tables compare each group with its own baseline. Baseline symptom counts differ. The report does not establish noninferiority or superior symptom control.
- Symptoms improved in both groups. The later diary means favor usual care numerically on these measures. The report does not provide a formal noninferiority comparison.
Advances in Gerontology / Uspekhi Gerontologii. 2013;26(2):309–314. PMID 28976156. · Journal article — commercial reproduction
About Chitomur
Identity / background source ↗
Research background
Institute reports describe adjunctive Chitomur in people with urinary symptoms, including a comparison in women with overactive bladder. Background treatment and outcome reporting limit attribution.
- Compound class
- Archival preparation lead
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Two 50-person oral studies: placebo comparison for prostate symptoms and usual-care comparison for overactive bladder.
Study methods
The Russian reports describe 30 participants receiving Chitomur and 20 controls in each study. Masking and between-group comparisons have reporting limitations.
Independent replication
New citations are not automatically independent replication; shared programs and translated reports require cohort checks
Source access
Indexed abstracts and Russian full-article reproductions with methods and tables.
Safety evidence
Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved
Open a topic for the evidence assessment.
Findings by study
Randomized study in people · 2013
Oral Chitomur versus usual treatment in women with overactive bladder
Urgency episodes fell from 4.05 to 2.83 with Chitomur and from 4.62 to 3.11 with usual care around day 15. Later counts were 3.26 and 2.67, respectively.
Study notes and original source
Oral Chitomur versus usual treatment in women with overactive bladder
Oral bladder tissue peptide preparation. · Journal article — commercial reproduction
V. G. Gomberg, A. P. Ryzhak, R. V. Lyutov · Advances in Gerontology / Uspekhi Gerontologii. 2013;26(2):309–314. PMID 28976156.
Urgency episodes fell from 4.05 to 2.83 with Chitomur and from 4.62 to 3.11 with usual care around day 15. Later counts were 3.26 and 2.67, respectively.
Results and tables
Reported findings and study design
Chitomur 30 versus usual care 20. Bladder diaries and validated symptom questionnaires at baseline and around 15 and 45 days from treatment start.
Population or model 50 women aged 48–80 with overactive bladder. Chitomur 30, usual care 20.
Dose, route and schedule
Two capsules twice daily with meals for 15 days, beginning after a three-day bladder diary. Capsule peptide mass is unspecified in this paper. The comparator received usual treatment. The discussion identifies muscarinic antagonists but gives no drug or dose.
Protocol source ↗ · Russian full-article reproduction, methods and Tables 1 and 3–6. Indexed abstract cross-checked.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Urgency episodes · around day 15 | 4.05 → 2.83 vs 4.62 → 3.11 | Chitomur versus usual care, each compared with its own baseline. Later values 3.26 and 2.67. |
| Incontinence episodes · around day 15 | 1.34 → 0.83 vs 1.62 → 0.77 | Later values 0.91 and 0.61. Tables give within-group tests. |
| ICIQ-LUTS symptom score · around day 15 | 8.75 → 6.63 vs 8.25 → 5.72 | Later values 7.23 and 4.60. |
| Reported adverse events | 0/30 vs 7/20 | Usual-care events included dry mouth and constipation. The drugs and ascertainment protocol are unspecified. |
Tables 1 and 4 · bladder diaries
| Measure | Chitomur baseline / early / later | Usual care baseline / early / later |
|---|---|---|
| Voids per day | 9.69 / 8.64 / 8.12 | 10.17 / 8.85 / 7.62 |
| Urgency episodes | 4.05 / 2.83 / 3.26 | 4.62 / 3.11 / 2.67 |
| Incontinence episodes | 1.34 / 0.83 / 0.91 | 1.62 / 0.77 / 0.61 |
| Nighttime voids | 2.10 / 1.51 / 1.69 | 2.32 / 1.67 / 1.53 |
Printed means. Early is about day 15. Later is one month after the Chitomur course or 1.5 months after usual care began. Significance markers compare each arm with its own baseline.
Symptoms improved in both groups. The later diary means favor usual care numerically on these measures. The report does not provide a formal noninferiority comparison.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 50 women aged 48–80 with overactive bladder. Chitomur 30, usual care 20.
- Source reviewed
- Russian full-article reproduction, methods and Tables 1 and 3–6. Indexed abstract cross-checked.
Study limitations
- The reproduction describes blinded random allocation without explaining concealment or how masking worked. Comparator drug schedules are unspecified.
- Tables compare each group with its own baseline. Baseline symptom counts differ. The report does not establish noninferiority or superior symptom control.
Reviewed 2026-11-14.
Randomized study in people · 2013
Oral Chitomur versus capsule placebo in men with benign prostatic hyperplasia
Post-course peak urinary flow was 12.7 vs 9.4 mL/s and prostate symptom scores were 13.2 vs 15.6 with Chitomur versus placebo. Prostate volume showed no significant change.
Study notes and original source
Oral Chitomur versus capsule placebo in men with benign prostatic hyperplasia
Oral calf bladder-derived peptide preparation. · Journal article — commercial reproduction
V. G. Gomberg, A. P. Ryzhak, R. V. Lyutov · Advances in Gerontology / Uspekhi Gerontologii. 2013;26(3):476–480. PMID 24640697.
Post-course peak urinary flow was 12.7 vs 9.4 mL/s and prostate symptom scores were 13.2 vs 15.6 with Chitomur versus placebo. Prostate volume showed no significant change.
Results and tables
Reported findings and study design
Chitomur 30 versus capsule placebo 20. Uroflowmetry, post-void residual volume, prostate ultrasound, and IPSS and quality-of-life questionnaires.
Population or model 50 men aged 62–83 with benign prostatic hyperplasia. Chitomur 30, capsule placebo 20.
Dose, route and schedule
Two 10 mg capsules twice daily with meals for 15 days (40 mg/day as reported). The comparator received placebo capsules. Methods place the post-course visit on day 16. The results narrative also uses day 14.
Protocol source ↗ · Russian full-article reproduction, methods and Tables 1–2. Indexed citation and abstract cross-checked. The indexed second-author initials differ from the reproduction.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Peak urinary flow · post-course | 12.7 vs 9.4 mL/s | Chitomur versus placebo. One month later, 10.36 vs 8.3 mL/s. · Table 1 marks p < 0.001 versus placebo at the post-course visit only. |
| Post-void residual urine · post-course | 23.2 vs 72.1 mL | One month later, 48.7 vs 69.8 mL. · Table 1 marks p < 0.001 versus placebo at both times. |
| International Prostate Symptom Score · post-course | 13.2 vs 15.6 points | One month later, 15.7 vs 17.9. The table gives a single 17.4-point baseline. · Table 2 marks p < 0.001 versus placebo at the post-course visit only. |
| Prostate volume and mean flow | No significant prostate-volume change | The table gives no significance marker for mean urinary flow. |
| Adverse events | None reported among Chitomur recipients | The paper gives no systematic harms table. |
Tables 1–2 · urinary measures by visit
| Measure | Single baseline column | Chitomur post-course | Placebo post-course | Chitomur one month later | Placebo one month later |
|---|---|---|---|---|---|
| Peak flow (mL/s) | 8.9 ± 0.8 | 12.7 ± 0.8 | 9.4 ± 1.4 | 10.36 ± 0.9 | 8.3 ± 1.7 |
| Mean flow (mL/s) | 4.1 ± 0.7 | 4.7 ± 1.3 | 4.2 ± 1.6 | 4.4 ± 1.5 | 3.9 ± 1.7 |
| Residual urine (mL) | 77.4 ± 16.1 | 23.2 ± 8.9 | 72.1 ± 19.2 | 48.7 ± 10.5 | 69.8 ± 13.7 |
| IPSS | 17.4 ± 0.9 | 13.2 ± 1.2 | 15.6 ± 2.2 | 15.7 ± 1.1 | 17.9 ± 3.1 |
| Quality-of-life index | 3.3 ± 0.2 | 2.4 ± 0.3 | 2.9 ± 0.5 | 2.8 ± 0.3 | 3.2 ± 0.6 |
Printed means and ± terms. The report gives one baseline column and inconsistent post-course timing. Peak flow and IPSS moved back toward baseline at follow-up.
The small study reported differences in urinary symptoms and function; prostate size did not measurably change. The conflict about masking limits confidence.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 50 men aged 62–83 with benign prostatic hyperplasia. Chitomur 30, capsule placebo 20.
- Source reviewed
- Russian full-article reproduction, methods and Tables 1–2. Indexed citation and abstract cross-checked. The indexed second-author initials differ from the reproduction.
Study limitations
- Methods describe a blinded randomized study and the conclusion calls it open. The accessible report does not explain concealment, masking or placebo contents.
- Tables use a single baseline column and the reported endpoint timing varies. The sample and follow-up are too limited to characterize uncommon harms.
Reviewed 2026-11-14.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗